University of Missouri Research Reactor supplying radioisotope for new cancer drug

(University of Missouri-Columbia) Scientists at the University of Missouri’s Research Reactor (MURR) identified promising properties of the radioisotope lutetium-177 (Lu-177), which can be used to treat cancer. Recently the U.S. FDA approved a Lu-177 based drug, Lutathera® (lutetium Lu-177 dotatate), to treat certain types of tumors that can occur in the gastrointestinal tract and pancreas. MURR is the sole US supplier of Lu-177 for use in Lutathera®, which was developed by Advanced Accelerator Applications.